J&J receives three subpoenas

Johnson & Johnson has received separate subpoenas from US Attorney’s Offices in Philadelphia, Boston and San Francisco related to marketing of three prescription drugs. The drugs at issue are schizophrenia and bipolar treatment Risperdal, marketed by Janssen, epilepsy treatment Topamax by Ortho-McNeil and heart-failure drug Natrecor by Scios. The investigations have been previously disclosed. The latest subpoenas seek information concerning corporate supervision and oversight of the J&J subsidiaries, which sell the drugs. The new subpoenas arrived at J&J’s corporate headquarters late last week, according to published reports. J&J said it plans to cooperate in responding to the subpoenas.
You must be a registered member of MMM to post a comment.

Next Article in Channel


Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.